7/102 sources · 2 publishersUpdated Oct 22, 11:34 UTC
CareDx reports AlloSure Kidney data linking elevated levels to transplant risk
CareDx presented AlloSure Kidney study results at the American Society of Nephrology Kidney Week 2026. The data showed 49% fewer biopsies with dd-cfDNA monitoring and linked elevated test levels to a nearly three-fold higher risk of adverse graft outcomes.
Why it matters
The findings support the use of CareDx's AlloSure Kidney test for kidney-transplant monitoring and risk assessment. The reported reduction in biopsies could affect how transplant patients are monitored, while the higher-risk association may help identify patients needing closer follow-up.
Key facts
- 1CareDx presented AlloSure Kidney results at the American Society of Nephrology Kidney Week 2026. tradingview.com
- 2The study reported 49% fewer biopsies for patients monitored with dd-cfDNA than for patients receiving surveillance biopsies. investing.com
- 3Elevated AlloSure Kidney levels were associated with a three-fold higher risk of allograft loss. investing.com
Open questions
- Material 1 describes the elevated-level association as a nearly three-fold risk, while material 2 states a three-fold risk.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.